As of March 31, 2025, the Company had cash of approximately $13.1 million. Subsequent to the end of the quarter, in May 2025, the Company completed a public offering with a single healthcare focused institutional investor for gross proceeds of approximately $5 million, before deducting placement agent fees and other estimated offering expenses. The Company believes that the cash on hand as of March 31, 2025 in addition to the $5 million public offering, is sufficient to fund planned operations into the second half of 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- CNS Pharmaceuticals Raises $5M in Public Offering
- CNS Pharmaceuticals acquires Orphan Drug Designation for TPI 287
- CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants
- CNS Pharmaceuticals Advances TPI 287 for Glioblastoma
- CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue